GLPwatch
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Rev Med Liege · 2016
Last updated 2026-05-28Two large studies found that two diabetes drugs—liraglutide (a GLP-1 drug) and empagliflozin (an SGLT2 drug)—reduced major heart problems by 13% and 14%, heart-related deaths by 22% and 38%, and deaths from any cause by 15% and 32%. Both drugs also lowered the risk of kidney problems by 22% and 39% in people with type 2 diabetes and high heart disease risk.
AI summary of the abstract below.
| Journal | Rev Med Liege, 2016 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction, Chronic Kidney Disease |
Abstract
Type 2 diabetes (T2D), often associated with arterial hypertension, represents a high risk of cardiovascular disease and nephropathy. Two clinical trials demonstrate the superiority versus a placebo of two antidiabetic drugs in patients with T2D and high cardiovascular risk : empagliflozin, an inhibitor of sodium-glucose type 2 (SGLT2) cotransporters, in EMPA-REG OUTCOME and liraglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptors, in LEADER. Both medications showed a significant reduction in major cardiovascular events (-14 and -13 %, respectively), cardiovascular mortality (-38 and -22%), all-cause mortality (-32 and -15 %) and renal events (-39 et -22 %). The underlying protective mechanisms remain controverted. Ongoing studies should allow to decide whether the benefits are specific to each molecule or may be attributed to a class effect.
Verbatim abstract via PubMed 28383832 ↗